Best eCOA platforms for clinical trials in 2026

Compare features

Compare 8 eCOA platforms by their documented instrument support, compliance, multilingual use, capture modes, setup and pricing basis. WeGuide is included for clinical trials and research studies that connect electronic assessments with ongoing participant engagement and follow-up. Each feature links to its public source.

Best forSponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.

Updated Nov 13, 20268 tools compared

What is eCOA software?

eCOA stands for electronic clinical outcome assessment. It is software for recording how participants feel or function through patient questionnaires, clinician or caregiver observations, and structured performance tasks. ePRO is the patient-reported part of this broader category.

Background: FDA clinical outcome assessment guide

What this software typically does

  • Collect electronic questionnaires and assessments
  • Schedule assessments and track completion
  • Keep assessment records and connect study data
Compare features

Compare product features

See documented feature support at a glance. Select a symbol for the explanation and source. Double checks indicate documented extra capabilities; unknown does not mean unavailable.

Products are not ranked. Table order is chosen for each guide and does not indicate a recommendation.

Select a symbol to read its evidence and source. Scroll sideways for all features.

Documented feature support for each product. Symbols describe individual features, not overall product ratings.
SoftwareValidated instrument library and licensingRegulatory compliance and track recordGlobal scale and languagesCapture modes and integrationsTime to launch and self-service buildPublished pricing and terms
Medidata eCOA

Extended support

A reusable instrument library is paired with a validated instrument license-management service.

Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.

2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.

Source

Supported

Part 11, Annex 11 and ICH E6 statements are documented; the approval claim is company-wide.

Supported means: Relevant trial or security controls are stated.

Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.

Source

Supported

Languages and study volumes are documented; this note does not establish multicountry use.

Supported means: Multicountry use or multilingual/localized participant support is documented.

200+ languages and dialects, 1,600+ eCOA studies, 90K+ sites and 460+ sponsors.

Source

Supported

BYOD, provisioned devices and Rave data flow are documented; listing Sensor Cloud does not establish sensor integration.

Supported means: Electronic outcome capture and a connection to another trial system or device are documented.

BYOD (iOS, Android), provisioned devices and web; data flows into Rave EDC; Sensor Cloud is listed among Patient Cloud applications.

Source

Extended support

Study builders configure questionnaires in Designer, with an average eight-week study start.

Extended support means: Study teams can configure the study themselves, with a stated build or launch timeframe.

Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.

Source

Supported

Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.

No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.

Source
Castor

Extended support

Validated instruments are available, with licensing and validation managed by Professional Services.

Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.

Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.

Source

Supported

Part 11 and GxP compliance are stated; approval counts are not published.

Supported means: Relevant trial or security controls are stated.

Fully validated, 21 CFR Part 11 and GxP compliant platform used in 6,100+ trials; no regulatory approval counts published.

Source

Supported

Language support is documented; this note does not establish multicountry use.

Supported means: Multicountry use or multilingual/localized participant support is documented.

80+ languages through translation services, 10+ pre-translated interface languages and 24/7 support.

Source

Supported

App, web and EDC connections are documented; wearable or sensor capture is not.

Supported means: Electronic outcome capture and a connection to another trial system or device are documented.

BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.

Source

Extended support

Self-service builds go live in weeks; managed builds reach UAT in four to eight weeks.

Extended support means: Study teams can configure the study themselves, with a stated build or launch timeframe.

Self-service and low-complexity eCOA builds go live in weeks; managed builds reach UAT in 4 to 8 weeks.

Source

Supported

Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.

Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.

Source
Clario

Supported

Validated libraries and science services are documented; managed licensing is not established.

Supported means: A library of outcome-assessment instruments is documented.

Pre-built, validated assessment libraries, the Rapid Start assessment catalog and an eCOA Science Services team with named scientists.

Source

Supported

ISO/SOC certifications are stated; this note does not establish a public certificate or audit report.

Supported means: Relevant trial or security controls are stated.

States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.

Source

Extended support

The note reports studies across countries and languages.

Extended support means: Both multicountry use and multilingual/localized participant support are documented.

Studies in over 120 countries and over 100 languages; 25 years of DCT and hybrid trials.

Source

Extended support

BYOD and provisioned devices are offered with integrated, pre-validated connected devices.

Extended support means: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.

BYOD, web or provisioned devices, plus pre-validated connected devices (CGM, glucose meters, Opal motion sensors) integrated with the eCOA device.

Source

Supported

Vendor-delivered oncology deployment timing is stated; a self-service designer is not documented.

Supported means: A study build process, self-service builder or launch timeframe is documented.

eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.

Source

Unknown

Sales contact alone does not establish a published pricing model, prices or contract terms.

The available evidence does not establish this feature. This does not mean it is unavailable.

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
WeGuide

Supported

Outcome forms and licensing support are described; confirm author approval and the managed licensing scope for each selected instrument before assuming the extended definition is met.

Supported means: A library of outcome-assessment instruments is documented.

WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.

Source

Supported

Public statements establish the documented-support level; no public certificate or audit report establishes extended support.

Supported means: Relevant trial or security controls are stated.

WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.

Source

Extended support

Published multicountry research and multilingual participant workflows meet the shared definition.

Extended support means: Both multicountry use and multilingual/localized participant support are documented.

WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.

Source

Supported

Electronic capture and system connections are documented; the source does not establish provisioned-device fleet support.

Supported means: Electronic outcome capture and a connection to another trial system or device are documented.

Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.

Source

Extended support

Team-configurable study workflows and a stated configuration timeframe meet the same launch definition applied to other products.

Extended support means: Study teams can configure the study themselves, with a stated build or launch timeframe.

The no-code study builder supports team configuration; WeGuide states a typical two-to-four-week configuration period with implementation support.

Source

Supported

Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.

WeGuide publishes a per-study quote basis. Contact the team for a study-specific quote; numerical prices are not published.

Source
Kayentis

Extended support

The questionnaire library is paired with licensing and validation handled by language-service partners.

Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.

Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.

Source

Supported

Supported means: Relevant trial or security controls are stated.

States a strong foundation in supporting labeling claims and NDAs without counts; 2021 brochure documents Part 11, GDPR and GAMP5 validation.

Source

Extended support

The cited release reports trials across countries and languages.

Extended support means: Both multicountry use and multilingual/localized participant support are documented.

280+ clinical trials in 85 countries and 120 languages (2023 release).

Source

Extended support

BYOD and provisioned capture are offered with wearable connections.

Extended support means: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.

BYOD, provisioned devices, web browser and interview mode; connects to IRT, patient portals, wearables and EDC/CDMS.

Source

Supported

Vendor-led setup is described; timelines and self-service tooling are not published.

Supported means: A study build process, self-service builder or launch timeframe is documented.

Set-up is vendor-led with protocol review and a questionnaire library; no timelines or self-service tooling published.

Source

Unknown

Sales contact alone does not establish a published pricing model, prices or contract terms.

The available evidence does not establish this feature. This does not mean it is unavailable.

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Medable

Supported

A validated library is documented; licensing services are not described.

Supported means: A library of outcome-assessment instruments is documented.

400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.

Source

Supported

Supported means: Relevant trial or security controls are stated.

States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.

Source

Extended support

The note documents deployment across countries and localized participant support.

Extended support means: Both multicountry use and multilingual/localized participant support are documented.

80+ countries and 120+ locales; device logistics from six global depots to 65+ countries.

Source

Extended support

BYOD and provisioned devices are documented alongside sensors and clinical-system connectors.

Extended support means: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.

eCOA, eConsent, TeleVisit and devices in one platform, BYOD or provisioned, with sensors and connectors to other clinical systems.

Source

Supported

A no-code builder and launch timing are documented; study-team self-service is not explicit.

Supported means: A study build process, self-service builder or launch timeframe is documented.

Study Studio is a no-code visual builder; studies that took 16 to 20 weeks go live in 4 to 6 weeks, some in a day.

Source

Supported

A monthly device-provisioning model is described; platform prices are not published.

Supported means: A production pricing basis, model or contract terms beyond a sales contact are published.

Platform prices not published; device provisioning is described as one all-inclusive monthly rate, without an amount.

Source
Signant

Extended support

The library includes author-approved instruments with scale licensing and management support.

Extended support means: A validated or instrument-author-approved library plus managed instrument licensing are documented.

Library of 50+ instruments, many pre-approved by authors; scale licensing and management support; 50+ clinical and eCOA experts.

Source

Unknown

A company-wide approval-history claim does not establish trial or security controls.

The available evidence does not establish this feature. This does not mean it is unavailable.

States it supported 25% of novel drug approvals across FDA and EMA in 2020-2025 (company-wide).

Source

Supported

Multicountry operations are documented; language support is not established by this note.

Supported means: Multicountry use or multilingual/localized participant support is documented.

Operates in 135+ countries, supports 600+ live eCOA studies and ran a BYOD study with 47,000+ participants.

Source

Supported

BYOD, provisioned capture and wearable sensors are listed; sensor integration is not established by this note.

Supported means: Electronic outcome capture and a connection to another trial system or device are documented.

Provisioned, web and BYOD deployment, ePRO and complex ClinRO, and wearable sensors through the Ametris acquisition.

Source

Supported

Vendor-delivered builds are described; a self-service designer is not published.

Supported means: A study build process, self-service builder or launch timeframe is documented.

Automation gives '33% faster eCOA launch timelines'; builds are delivered by Signant, no self-service eCOA designer published.

Source

Unknown

Sales contact alone does not establish a published pricing model, prices or contract terms.

The available evidence does not establish this feature. This does not mean it is unavailable.

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
YPrime

Supported

Pre-validated libraries and licensing relationships are stated; managed licensing is not established.

Supported means: A library of outcome-assessment instruments is documented.

Instrument licensing relationships and pre-validated eCOA libraries; library size and science team not published.

Source

Supported

Part 11 and GxP compliance are stated; ISO certification remains in progress.

Supported means: Relevant trial or security controls are stated.

Documents GxP and 21 CFR Part 11 compliance and an open client-audit program; nearly 1,000 studies, no approval counts; ISO 27001 in progress.

Source

Extended support

Multicountry deployment and multilingual localization are both documented.

Extended support means: Both multicountry use and multilingual/localized participant support are documented.

Localization in 250+ languages and deployment in 100+ countries.

Source

Extended support

BYOD and provisioned capture are documented with wearables, glucometers and sensors.

Extended support means: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.

BYOD, provisioned or both; wearables, glucometers and sensors; integrated eCOA, IRT and eConsent with EDC data workflows.

Source

Supported

Vendor-delivered builds are described; a self-service designer is not published.

Supported means: A study build process, self-service builder or launch timeframe is documented.

Claims 47% faster eCOA study startup; builds are vendor-delivered, no self-service designer published.

Source

Unknown

Sales contact alone does not establish a published pricing model, prices or contract terms.

The available evidence does not establish this feature. This does not mean it is unavailable.

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
  • Supported
  • Extended support
  • Not available
  • Unknown
What do the checks mean for this guide?

Every product uses the same definitions. Double checks indicate documented extra capabilities in that column; they do not indicate an overall winner. Unknown means the available sources do not establish support.

Validated instrument library and licensing
Supported: A library of outcome-assessment instruments is documented.
Extended support: A validated or instrument-author-approved library plus managed instrument licensing are documented.
Regulatory compliance and track record
Supported: Relevant trial or security controls are stated.
Extended support: Relevant trial controls plus a public ISO/SOC certificate or audit report are documented; a certification claim or logo alone is insufficient.
Global scale and languages
Supported: Multicountry use or multilingual/localized participant support is documented.
Extended support: Both multicountry use and multilingual/localized participant support are documented.
Capture modes and integrations
Supported: Electronic outcome capture and a connection to another trial system or device are documented.
Extended support: Capture on participant-owned and provisioned devices plus wearable or sensor integration are documented.
Time to launch and self-service build
Supported: A study build process, self-service builder or launch timeframe is documented.
Extended support: Study teams can configure the study themselves, with a stated build or launch timeframe.
Published pricing and terms
Supported: A production pricing basis, model or contract terms beyond a sales contact are published.
Extended support: Numerical production prices or a free production option with its conditions are published.
Read the detailed feature comparison

Select a feature label for its details and source. Scroll sideways for all features.

Feature statements for each product, with public sources. Products appear in editorial order.
SoftwareValidated instrument library and licensingRegulatory compliance and track recordGlobal scale and languagesCapture modes and integrationsTime to launch and self-service buildPublished pricing and terms
Medidata eCOA
2,500+ COAs + license management — details and source

2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.

Source
Part 11, Annex 11 + ICH E6 statements — details and source

Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.

Source
200+ languages/dialects + 1,600+ studies — details and source

200+ languages and dialects, 1,600+ eCOA studies, 90K+ sites and 460+ sponsors.

Source
BYOD, web + direct Rave EDC data flow — details and source

BYOD (iOS, Android), provisioned devices and web; data flows into Rave EDC; Sensor Cloud is listed among Patient Cloud applications.

Source
Designer; average 8-week start (vendor claim) — details and source

Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.

Source
Prices unpublished; rental and contract terms public — details and source

No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.

Source
Castor
Validated library + managed licensing — details and source

Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.

Source
Part 11 + GxP stated; no approval counts published — details and source

Fully validated, 21 CFR Part 11 and GxP compliant platform used in 6,100+ trials; no regulatory approval counts published.

Source
80+ languages via translation services — details and source

80+ languages through translation services, 10+ pre-translated interface languages and 24/7 support.

Source
App, web + SMS; wearables not documented — details and source

BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.

Source
Self-service; managed UAT 4–8 weeks (vendor claim) — details and source

Self-service and low-complexity eCOA builds go live in weeks; managed builds reach UAT in 4 to 8 weeks.

Source
Fixed-scope quotes; prices not published — details and source

Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.

Source
Clario
Validated libraries + eCOA science services — details and source

Pre-built, validated assessment libraries, the Rapid Start assessment catalog and an eCOA Science Services team with named scientists.

Source
ISO 27001 + SOC 2 Type II stated — details and source

States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.

Source
120+ countries + 100+ languages — details and source

Studies in over 120 countries and over 100 languages; 25 years of DCT and hybrid trials.

Source
BYOD, web + connected devices — details and source

BYOD, web or provisioned devices, plus pre-validated connected devices (CGM, glucose meters, Opal motion sensors) integrated with the eCOA device.

Source
From 2 weeks for early oncology (vendor claim) — details and source

eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.

Source
Sales contact; prices and terms not published — details and source

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
WeGuide
Instrument library and licensing support — details and source

WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.

Source
Trial/privacy controls and ISO certification stated — details and source

WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.

Source
BRACE in five countries; multilingual studies — details and source

WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.

Source
Participant app, forms and EDC/device connections — details and source

Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.

Source
No-code configuration; typically 2–4 weeks — details and source

The no-code study builder supports team configuration; WeGuide states a typical two-to-four-week configuration period with implementation support.

Source
Per-study quote; amounts not published — details and source

WeGuide publishes a per-study quote basis. Contact the team for a study-specific quote; numerical prices are not published.

Source
Kayentis
Questionnaire library + licensing partners — details and source

Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.

Source
Part 11 + GAMP5 stated (2021 brochure) — details and source

States a strong foundation in supporting labeling claims and NDAs without counts; 2021 brochure documents Part 11, GDPR and GAMP5 validation.

Source
85 countries + 120 languages (2023 release) — details and source

280+ clinical trials in 85 countries and 120 languages (2023 release).

Source
BYOD, web, interview + wearable links — details and source

BYOD, provisioned devices, web browser and interview mode; connects to IRT, patient portals, wearables and EDC/CDMS.

Source
Vendor-led; timelines not published — details and source

Set-up is vendor-led with protocol review and a questionnaire library; no timelines or self-service tooling published.

Source
Sales contact; prices and terms not published — details and source

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Medable
400+ instruments; licensing services not described — details and source

400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.

Source
Part 11/Annex 11 stated; no approval counts — details and source

States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.

Source
80+ countries + 120+ locales — details and source

80+ countries and 120+ locales; device logistics from six global depots to 65+ countries.

Source
eCOA, eConsent, TeleVisit + sensors — details and source

eCOA, eConsent, TeleVisit and devices in one platform, BYOD or provisioned, with sensors and connectors to other clinical systems.

Source
No-code; 4–6 weeks (vendor claim) — details and source

Study Studio is a no-code visual builder; studies that took 16 to 20 weeks go live in 4 to 6 weeks, some in a day.

Source
Prices unpublished; monthly device rate described — details and source

Platform prices not published; device provisioning is described as one all-inclusive monthly rate, without an amount.

Source
Signant
50+ instruments + licensing support — details and source

Library of 50+ instruments, many pre-approved by authors; scale licensing and management support; 50+ clinical and eCOA experts.

Source
25% FDA/EMA approvals, 2020–25 (company-wide claim) — details and source

States it supported 25% of novel drug approvals across FDA and EMA in 2020-2025 (company-wide).

Source
135+ countries + 600+ live eCOA studies — details and source

Operates in 135+ countries, supports 600+ live eCOA studies and ran a BYOD study with 47,000+ participants.

Source
BYOD, web, ClinRO + Ametris wearables — details and source

Provisioned, web and BYOD deployment, ePRO and complex ClinRO, and wearable sensors through the Ametris acquisition.

Source
Vendor-led; 33% faster launch (vendor claim) — details and source

Automation gives '33% faster eCOA launch timelines'; builds are delivered by Signant, no self-service eCOA designer published.

Source
Sales contact; prices and terms not published — details and source

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
YPrime
Pre-validated libraries + licensing relationships — details and source

Instrument licensing relationships and pre-validated eCOA libraries; library size and science team not published.

Source
Part 11 stated; ISO 27001 in progress — details and source

Documents GxP and 21 CFR Part 11 compliance and an open client-audit program; nearly 1,000 studies, no approval counts; ISO 27001 in progress.

Source
250+ languages + 100+ countries — details and source

Localization in 250+ languages and deployment in 100+ countries.

Source
BYOD, wearables + eCOA/IRT/eConsent — details and source

BYOD, provisioned or both; wearables, glucometers and sensors; integrated eCOA, IRT and eConsent with EDC data workflows.

Source
Vendor-led; 47% faster startup (vendor claim) — details and source

Claims 47% faster eCOA study startup; builds are vendor-delivered, no self-service designer published.

Source
Sales contact; prices and terms not published — details and source

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source

The short list

Products in editorial order
  • Medidata eCOAStudy fit: large sponsors and CROs that already run Rave EDC and want eCOA in the same platform
  • CastorStudy fit: biotech, device and academic teams that want eCOA, eConsent and EDC in one platform with a self-service option
  • ClarioStudy fit: global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints
  • WeGuideStudy fit: clinical trials and research studies where ongoing participant engagement is central, with electronic assessments, reminders and follow-up in one study app
  • KayentisStudy fit: phase II-III sponsors that want a specialist eCOA vendor with site and patient helpdesk support
  • MedableStudy fit: sponsors and CROs that want a no-code eCOA build tool with eConsent and televisits on one platform
  • Signant eCOAStudy fit: CNS and other complex-endpoint trials that need clinician ratings, licensing support and global logistics
  • YPrimeStudy fit: sponsors that want eCOA, IRT and eConsent from one vendor across many languages

Compare at a glance

SoftwareOwn-phone app (BYOD)Wearable dataScalePricing model
Medidata eCOA

Yes (iOS, Android); also web and provisioned devices

Source

Needs facts

Needs facts

No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)

Source
Castor

Castor Connect native app (iOS, Android) or browser

Source

Through API integrations; no native consumer platform named

Source

6,100+ clinical trials

Source

Per-study flat-rate license, no per-subject fees, quote within five business days

Source
Clario

Yes; also web and provisioned devices

Source

Connected devices: CGM, glucose meters, Opal motion sensors

Source

Studies in 120+ countries and 100+ languages

Source

Not published

Source
WeGuide

Native iOS and Android apps under your own App Store name, or the WeGuide app

Source

Native Garmin integration; Apple Health and Health Connect data routes; Fitbit Air support is listed. For other devices, available data depends on what their apps share with the phone health store.

Source

BRACE in five countries and INHERIT in ten languages (vendor-reported research examples, not EDC or CTMS deployments)

Source

Quoted per study, with hosting, support and modules included. Email hello@weguide.health for a study-specific quote; price amounts are not published.

Source
Kayentis

Yes; also provisioned devices, web and interview mode

Source

Needs facts

280+ trials in 85 countries and 120 languages (2023)

Source

Not published

Source
Medable

Participant app on iOS and Android, or web

Source

Withings partnership and Apple HealthKit use; no public list of consumer platforms

Source

80+ countries, 120+ locales, nearly 400 trials

Source

Not published (device provisioning described as one all-inclusive monthly rate, no amount)

Source
Signant eCOA

Yes; also web and provisioned devices

Source

Wearable sensors through the Ametris (formerly ActiGraph) acquisition

Source

135+ countries, 600+ live eCOA studies, largest BYOD study 47,000+ participants

Source

Not published

Source
YPrime

Yes; provisioned devices or both in one study

Source

Wearables, glucometers and sensors

Source

Nearly 1,000 studies in 100+ countries; 250+ eCOA languages

Source

Not published

Source

Product details

Medidata eCOA

Study fit: large sponsors and CROs that already run Rave EDC and want eCOA in the same platform

Medidata eCOA lists 2,500+ COAs, 200+ languages and dialects and 1,600+ studies, and data flows straight into Rave EDC. Study builders can configure it in Medidata Designer, with an average study start of 8 weeks. Prices are not published.

Validated instrument library and licensing

2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.

Source
Regulatory compliance and track record

Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.

Source
Global scale and languages

200+ languages and dialects, 1,600+ eCOA studies, 90K+ sites and 460+ sponsors.

Source
Capture modes and integrations

BYOD (iOS, Android), provisioned devices and web; data flows into Rave EDC; Sensor Cloud is listed among Patient Cloud applications.

Source
Time to launch and self-service build

Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.

Source
Published pricing and terms

No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.

Source
Pricing model
No prices published; the Patient Cloud service descriptions publish contract terms (devices on a rental basis, caps on fee adjustments, early-termination fees)Source
Security certifications
ISO 27001:2022, ISO 27017:2015, ISO 27018:2019, ISO 27701:2019, SOC 2+ Type IISource
Headquarters
New York, NY (350 Hudson Street, per ISO certificate)Source

Less suitable for teams that need published prices or a self-serve contract for a single small study.

View the Medidata profile Visit website

Castor

Study fit: biotech, device and academic teams that want eCOA, eConsent and EDC in one platform with a self-service option

Castor offers a validated instrument library with licensing handled by its services team, self-service builds that go live in weeks and a published pricing process with an entry package for early-stage companies. Its global reach and regulatory track record are smaller than the enterprise platforms'.

Validated instrument library and licensing

Library of validated instruments (EORTC, FACT-G, EQ-5D, SF-36, PROMIS); Professional Services manages scale licensing and validation; library size not published.

Source
Regulatory compliance and track record

Fully validated, 21 CFR Part 11 and GxP compliant platform used in 6,100+ trials; no regulatory approval counts published.

Source
Global scale and languages

80+ languages through translation services, 10+ pre-translated interface languages and 24/7 support.

Source
Capture modes and integrations

BYOD app, browser, SMS and messaging apps, site tablet mode and provisioned devices; integrates with major EDCs via REST API and webhooks. Wearable or sensor capture not documented.

Source
Time to launch and self-service build

Self-service and low-complexity eCOA builds go live in weeks; managed builds reach UAT in 4 to 8 weeks.

Source
Published pricing and terms

Pricing process published: itemized, fixed-scope proposal with change-control terms within 5 business days, plus a Castor Essentials package for early-stage companies; no prices.

Source
Pricing model
Per-study flat-rate license, no per-subject fees, quote within five business daysSource
Compliance claims
Listed: FDA 21 CFR Part 11, EU Annex 11, ICH E6(R3) GCP, EU GDPR, EU MDR 2017/745 (PMCF)Source
Security certifications
ISO/IEC 27001:2022 (certificate published); ISO 9001 and NEN 7510 stated in its help centerSource
API and integrations
Open API; HL7 FHIR alignment; EHR, lab and wearable integrationsSource

Less suitable for global pivotal programs that need the largest instrument libraries and published regulatory track records

View the Castor profile Visit website

Clario

Study fit: global pivotal trials that combine eCOA with cardiac, respiratory, imaging or sensor endpoints

Clario has the deepest enterprise eCOA profile here: studies in 120+ countries and 100+ languages, a named eCOA science team and pre-validated assessment libraries. It says it has supported 70% of FDA and EMA new drug approvals since 2015 across its endpoints. Builds are delivered by Clario and prices are not published.

Validated instrument library and licensing

Pre-built, validated assessment libraries, the Rapid Start assessment catalog and an eCOA Science Services team with named scientists.

Source
Regulatory compliance and track record

States it has supported 70% of FDA and EMA new drug approvals since 2015 (company-wide, all endpoint types); ISO 27001:2022 and SOC 2 Type II are published separately.

Source
Global scale and languages

Studies in over 120 countries and over 100 languages; 25 years of DCT and hybrid trials.

Source
Capture modes and integrations

BYOD, web or provisioned devices, plus pre-validated connected devices (CGM, glucose meters, Opal motion sensors) integrated with the eCOA device.

Source
Time to launch and self-service build

eCOA Swift deploys early-phase oncology trials in as little as 2 weeks and Rapid Start offers pre-configured assessments; builds are vendor-delivered, no self-service designer published.

Source
Published pricing and terms

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Pricing model
Not publishedSource
Security certifications
ISO/IEC 27001:2022 and SOC 2 Type IISource

Less suitable for teams that want to build and change their own study or need published pricing

View the Clario profile Visit website

WeGuide

Study fit: clinical trials and research studies where ongoing participant engagement is central, with electronic assessments, reminders and follow-up in one study app

Study fit source

WeGuide combines electronic outcome assessments with ongoing participant engagement for clinical trials and research studies. Teams connect assessments with consent, reminders and follow-up in a branded study app, with multilingual and wearable-data options. This supports study designs that need participants to stay involved between visits or over time, including investigator-led studies, cohorts and registries. Suitability depends on the assessments and workflows required, rather than study size alone. Confirm instrument licensing, assessment validation and any intensive site-entry or device-logistics needs.

Validated instrument library and licensing

WeGuide publishes an assessment-instrument library and describes instrument licensing and digital-migration support. Confirm permissions and validation responsibilities for each chosen instrument.

Source
Regulatory compliance and track record

WeGuide states ISO 27001:2022 certification and support for GDPR, HIPAA and 21 CFR Part 11. The public material does not provide the certificate or an audit report.

Source
Global scale and languages

WeGuide describes BRACE across five countries and INHERIT in ten languages. These are examples of participant outcome collection, rather than a claim of enterprise-scale eCOA deployment.

Source
Capture modes and integrations

Electronic participant outcome forms connect to existing EDC systems through the Integration Engine. Provisioned-device fleet delivery is not established by this source.

Source
Time to launch and self-service build

The no-code study builder supports team configuration; WeGuide states a typical two-to-four-week configuration period with implementation support.

Source
Published pricing and terms

WeGuide publishes a per-study quote basis. Contact the team for a study-specific quote; numerical prices are not published.

Source
Pricing model
Quoted per study, with hosting, support and modules included. Email hello@weguide.health for a study-specific quote; price amounts are not published.Source
Compliance claims
Supports 21 CFR Part 11 requirements (stated); EU Annex 11 not statedSource
Compliance claims
WeGuide states 21 CFR Part 11 and HIPAA support; confirm the study-specific validation scope and BAA requirements.Source
Security certifications
ISO 27001:2022 (stated; certificate not published); no SOC 2 claim foundSource

Less suitable for protocols requiring a fully managed global provisioned-device fleet or an enterprise EDC and drug-supply suite from the same provider; confirm the required capture modes and services.

View the WeGuide profile Visit website

Kayentis

Study fit: phase II-III sponsors that want a specialist eCOA vendor with site and patient helpdesk support

Kayentis is an eCOA specialist with 280+ trials in 85 countries and 120 languages, and its Clin'form app runs on BYOD, provisioned devices, web and interview mode. It does not publish build timelines, approval counts or prices.

Validated instrument library and licensing

Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.

Source
Regulatory compliance and track record

States a strong foundation in supporting labeling claims and NDAs without counts; 2021 brochure documents Part 11, GDPR and GAMP5 validation.

Source
Global scale and languages

280+ clinical trials in 85 countries and 120 languages (2023 release).

Source
Capture modes and integrations

BYOD, provisioned devices, web browser and interview mode; connects to IRT, patient portals, wearables and EDC/CDMS.

Source
Time to launch and self-service build

Set-up is vendor-led with protocol review and a questionnaire library; no timelines or self-service tooling published.

Source
Published pricing and terms

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Pricing model
Not publishedSource
Compliance claims
Part 11 and GDPR compliant, validated according to GAMP5 (2021 brochure)Source
Headquarters
France (offices in Meylan, Boston and Tokyo)Source

Less suitable for teams that want to build the study themselves or need published pricing

View the Kayentis profile Visit website

Medable

Study fit: sponsors and CROs that want a no-code eCOA build tool with eConsent and televisits on one platform

Medable pairs a large library (400+ validated instruments, 120+ locales) with Study Studio, a no-code builder its site says takes studies live in 4 to 6 weeks. It publishes Part 11, Annex 11, HIPAA and GDPR compliance but no regulatory approval counts or prices.

Validated instrument library and licensing

400+ pre-built, validated instruments in a reusable library with AI-assisted instrument generation; licensing services are not described on the pages checked.

Source
Regulatory compliance and track record

States compliance with 21 CFR Part 11, Annex 11, HIPAA, GDPR and ICH GCP and says its eCOA data can support primary endpoints in pivotal studies; deployed in nearly 400 trials, with no approval counts published.

Source
Global scale and languages

80+ countries and 120+ locales; device logistics from six global depots to 65+ countries.

Source
Capture modes and integrations

eCOA, eConsent, TeleVisit and devices in one platform, BYOD or provisioned, with sensors and connectors to other clinical systems.

Source
Time to launch and self-service build

Study Studio is a no-code visual builder; studies that took 16 to 20 weeks go live in 4 to 6 weeks, some in a day.

Source
Published pricing and terms

Platform prices not published; device provisioning is described as one all-inclusive monthly rate, without an amount.

Source
Pricing model
Not published (device provisioning described as one all-inclusive monthly rate, no amount)Source
Compliance claims
Part 11, Annex 11, HIPAA, GDPR and ICH GCP statedSource
Security certifications
No ISO 27001 or SOC 2 named publiclySource
API and integrations
Integrations with IRT, EDC, CTMS, EMR and lab systemsSource

Less suitable for teams that need published pricing or a published security certificate

View the Medable profile Visit website

Signant eCOA

Study fit: CNS and other complex-endpoint trials that need clinician ratings, licensing support and global logistics

Signant combines a 50+ instrument library, in-house licensing support and 50+ clinical and eCOA experts with operations in 135+ countries. It says it supported 25% of FDA and EMA novel drug approvals from 2020 to 2025 and now adds wearable sensors through Ametris. Builds are vendor-led and prices are not published.

Validated instrument library and licensing

Library of 50+ instruments, many pre-approved by authors; scale licensing and management support; 50+ clinical and eCOA experts.

Source
Regulatory compliance and track record

States it supported 25% of novel drug approvals across FDA and EMA in 2020-2025 (company-wide).

Source
Global scale and languages

Operates in 135+ countries, supports 600+ live eCOA studies and ran a BYOD study with 47,000+ participants.

Source
Capture modes and integrations

Provisioned, web and BYOD deployment, ePRO and complex ClinRO, and wearable sensors through the Ametris acquisition.

Source
Time to launch and self-service build

Automation gives '33% faster eCOA launch timelines'; builds are delivered by Signant, no self-service eCOA designer published.

Source
Published pricing and terms

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Pricing model
Not publishedSource

Less suitable for teams that need published pricing or a published security certificate

View the Signant profile Visit website

YPrime

Study fit: sponsors that want eCOA, IRT and eConsent from one vendor across many languages

YPrime covers 250+ languages and 100+ countries and integrates eCOA with its own IRT and eConsent. It documents Part 11 and GxP compliance and nearly 1,000 studies, but no approval counts, and its ISO 27001 certification is still in progress. Builds are vendor-led and prices are not published.

Validated instrument library and licensing

Instrument licensing relationships and pre-validated eCOA libraries; library size and science team not published.

Source
Regulatory compliance and track record

Documents GxP and 21 CFR Part 11 compliance and an open client-audit program; nearly 1,000 studies, no approval counts; ISO 27001 in progress.

Source
Global scale and languages

Localization in 250+ languages and deployment in 100+ countries.

Source
Capture modes and integrations

BYOD, provisioned or both; wearables, glucometers and sensors; integrated eCOA, IRT and eConsent with EDC data workflows.

Source
Time to launch and self-service build

Claims 47% faster eCOA study startup; builds are vendor-delivered, no self-service designer published.

Source
Published pricing and terms

Not published: no price, pricing model or contract terms on the vendor site; pricing by sales contact only.

Source
Pricing model
Not publishedSource
Compliance claims
GxP and 21 CFR Part 11 compliance; open client-audit programSource
Security certifications
ISO 27001 certification in progress (target 2027)Source

Less suitable for teams that need a self-service builder, published pricing or a current ISO 27001 certificate

View the YPrime profile Visit website

How we compare this software

This guide compares 8 products across the same feature topics. Each statement describes what the available public sources document, including limitations and study requirements.

Scope: Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.

  • Validated instrument library and licensing
  • Regulatory compliance and track record
  • Global scale and languages
  • Capture modes and integrations
  • Time to launch and self-service build
  • Published pricing and terms

A vendor’s published claim is not independent confirmation that a product will meet your study’s needs. Check deployment, validation, integrations and commercial terms with the vendor.

Outside this comparison: Not included in this comparison: Suvoda, Datacubed Health and Clinical ink.

Read the comparison method

Questions about eCOA software

What is an eCOA platform?

An eCOA (electronic clinical outcome assessment) platform captures patient-reported, clinician-reported, observer-reported and performance outcomes electronically in a clinical trial, on participants' own phones, provisioned devices, tablets at the site or the web, with time stamps and an audit trail.

Which eCOA platforms suit a large global pivotal trial?

On published scale, Medidata (200+ languages, 1,600+ eCOA studies), Clario (120+ countries, 100+ languages), Signant Health (135+ countries, 600+ live eCOA studies), YPrime (250+ languages, 100+ countries) and Kayentis (85 countries, 120 languages) all document global deployments. Medidata, Clario and Signant also publish company-wide figures on the share of FDA and EMA approvals their technology supported.

How long does an eCOA study take to set up?

Published figures vary: Medidata reports an average study start of 8 weeks, Medable 4 to 6 weeks with its no-code Study Studio, Castor 4 to 8 weeks for managed builds and weeks for self-service builds, and Clario as little as 2 weeks for its early-phase oncology package.

Can participants use their own phones (BYOD)?

The platforms here document participant-owned-device capture. Provisioned-device supply and management differ by vendor; check the feature notes and confirm the protocol’s device requirements.

How does eCOA differ from ePRO?

eCOA is electronic clinical outcome assessment, covering patient reports, clinician reports, observer reports and performance tasks. ePRO is the part reported directly by the participant. Check the vendor’s documented support for each assessment workflow.

Source